Shiraki K - Search Results

1

T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections.

Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. Furuta Y, et al. Among authors: shiraki k. Antiviral Res. 2009 Jun;82(3):95-102. doi: 10.1016/j.antiviral.2009.02.198. Epub 2009 Mar 6. Antiviral Res. 2009. PMID: 19428599 Free PMC article. Review.

2

In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.

Takahashi K, Furuta Y, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Shiraki K. Takahashi K, et al. Among authors: shiraki k. Antivir Chem Chemother. 2003 Sep;14(5):235-41. doi: 10.1177/095632020301400502. Antivir Chem Chemother. 2003. PMID: 14694986 Free article.

3

Favipiravir (T-705), a novel viral RNA polymerase inhibitor.

Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Furuta Y, et al. Among authors: shiraki k. Antiviral Res. 2013 Nov;100(2):446-54. doi: 10.1016/j.antiviral.2013.09.015. Epub 2013 Sep 29. Antiviral Res. 2013. PMID: 24084488 Free PMC article. Review.

4

Mechanism of action of T-705 against influenza virus.

Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. Furuta Y, et al. Among authors: shiraki k. Antimicrob Agents Chemother. 2005 Mar;49(3):981-6. doi: 10.1128/AAC.49.3.981-986.2005. Antimicrob Agents Chemother. 2005. PMID: 15728892 Free PMC article.

5

In vitro and in vivo activities of anti-influenza virus compound T-705.

Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K. Furuta Y, et al. Among authors: shiraki k. Antimicrob Agents Chemother. 2002 Apr;46(4):977-81. doi: 10.1128/AAC.46.4.977-981.2002. Antimicrob Agents Chemother. 2002. PMID: 11897578 Free PMC article.

6

Comparative efficacy of acyclovir and vidarabine on the replication of varicella-zoster virus.

Miwa N, Kurosaki K, Yoshida Y, Kurokawa M, Saito S, Shiraki K. Miwa N, et al. Among authors: shiraki k. Antiviral Res. 2005 Jan;65(1):49-55. doi: 10.1016/j.antiviral.2004.10.002. Antiviral Res. 2005. PMID: 15652971

7

Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus, and measles virus in vitro and their therapeutic efficacies for HSV-1 infection in mice.

Kurokawa M, Ochiai H, Nagasaka K, Neki M, Xu H, Kadota S, Sutardjo S, Matsumoto T, Namba T, Shiraki K. Kurokawa M, et al. Among authors: shiraki k. Antiviral Res. 1993 Oct;22(2-3):175-88. doi: 10.1016/0166-3542(93)90094-y. Antiviral Res. 1993. PMID: 8279811

8

Everolimus delayed and suppressed cytomegalovirus DNA synthesis, spread of the infection, and alleviated cytomegalovirus infection.

Tan L, Sato N, Shiraki A, Yanagita M, Yoshida Y, Takemura Y, Shiraki K. Tan L, et al. Among authors: shiraki a, shiraki k. Antiviral Res. 2019 Feb;162:30-38. doi: 10.1016/j.antiviral.2018.12.004. Epub 2018 Dec 10. Antiviral Res. 2019. PMID: 30543830

9

Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir.

Shiraki K, Tan L, Daikoku T, Takemoto M, Sato N, Yoshida Y. Shiraki K, et al. Antiviral Res. 2020 Aug;180:104829. doi: 10.1016/j.antiviral.2020.104829. Epub 2020 Jun 20. Antiviral Res. 2020. PMID: 32569704

10

T-705 (Favipiravir) suppresses tumor necrosis factor α production in response to influenza virus infection: A beneficial feature of T-705 as an anti-influenza drug.

Tanaka T, Kamiyama T, Daikoku T, Takahashi K, Nomura N, Kurokawa M, Shiraki K. Tanaka T, et al. Among authors: shiraki k. Acta Virol. 2017;61(1):48-55. doi: 10.4149/av_2017_01_48. Acta Virol. 2017. PMID: 28105854

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,013 results

Search Page